• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Cystic Fibrosis and Personalized Medicine: A Brief History

Slideshow

These concise summaries outline key developments in the evolution of a promising genetics-based approach to cystic fibrosis treatment.

Personalized medicine, also known as precision medicine, continues to advance as a genetics-based approach to treating patients with cystic fibrosis (CF). In this approach, personalized interventions are applied for patients who have specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Scroll through the slides below to find concise summaries of key developments in the evolution of personalized, or precision, medicine for patients with CF.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination / Image credit: ©Sherry Young/AdobeStock

Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination

April 18th 2024
Article

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Risk for CHD Higher for Women who Binge Drink vs Men: Daily Dose / image credit: ©New Africa/AdobeStock

Risk for CHD Higher for Women who Binge Drink vs Men: Daily Dose

April 17th 2024
Article

Your daily dose of the clinical news you may have missed.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Regulatory Submission / image credit obese man asleep / ©motortion/stock.adobe.com

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission

April 17th 2024
Article

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Tezepelumab for COPD Moves into Phase 3 Planning, Says Amgen / image credit Amgen logo ©MichaelVi/stock.adobe.com

Tezepelumab for COPD Moves into Phase 3 Planning

April 17th 2024
Article

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

© 2024 MJH Life Sciences

All rights reserved.